Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2102 vs Docetaxel + Trastuzumab + Pertuzumab in HER2+ Breast Cancer
NCT07003074Phase 3Recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Jun 2025
- Primary completion
- Jul 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of TQB2102 in breast cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Started Jun 2025; status: recruiting.
02
Drugs
TQB2102
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07003074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07003074.